Clinic
Baptist Health Hospitals
Baptist Health Hospitals was paid $2.97M by Medicaid between Jan 2018 and Dec 2024, across 163 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 11% of everything it billed.
33Billing provider infoBAPTIST HEALTH HOSPITALS
STUTTGART, AR 72160
STUTTGART, AR 72160
33aNPI1790773158assigned 10/10/2005
33bProvider typeRehabilitation Clinic/Center
28Total paid$2.97M
24GClaims212,309
24DCodes billed163
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Arkansas
Rank by total paid#15 of 27
Median peer was paid$3.03M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELLS, TROY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,650 | $283K | |
| 2019 | 36,130 | $374K | |
| 2020 | 30,730 | $393K | |
| 2021 | 36,276 | $564K | |
| 2022 | 36,500 | $619K | |
| 2023 | 26,554 | $435K | |
| 2024incomplete | 18,469 | $306K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 3,889 | 3,320 | $324K |
| 80053 | Comprehensive metabolic panel | 7.7% | 14,592 | 12,710 | $228K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.3% | 6,521 | 1,690 | $218K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 6.0% | 1,679 | 1,534 | $177K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.2% | 1,965 | 1,754 | $153K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.1% | 7,894 | 6,897 | $152K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.6% | 4,190 | 3,702 | $137K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.4% | 8,901 | 8,013 | $102K |
| 80050 | General health panel | 3.3% | 2,307 | 2,149 | $98K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 808 | 710 | $93K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 16,813 | 14,522 | $87K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.9% | 5,004 | 4,251 | $87K |
151 more codes
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 4,041 | $64K |
| 80061 | Lipid panel | 1.8% | 5,805 | $53K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 9,804 | $38K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 4,493 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 4,808 | $33K |
| 73560 | 1.1% | 1,500 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 1,573 | $31K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 290 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,726 | $29K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 479 | $29K |
| 81025 | <1% | 3,276 | $27K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,789 | $26K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 712 | $25K |
| 83880 | <1% | 1,902 | $25K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,279 | $22K |
| 87088 | <1% | 2,769 | $22K | |
| 87800 | <1% | 849 | $20K | |
| 81001 | <1% | 6,825 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,062 | $20K |
| 84484 | <1% | 3,388 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 419 | $19K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 419 | $19K |
| 74018 | <1% | 1,085 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 373 | $17K |
| 87428 | <1% | 248 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 178 | $15K |
| 80305 | <1% | 1,255 | $15K | |
| 87420 | <1% | 1,267 | $15K | |
| 87631 | <1% | 206 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 719 | $14K |
| 72100 | <1% | 700 | $14K | |
| 97161 | <1% | 260 | $13K | |
| 82550 | <1% | 3,268 | $13K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 345 | $13K |
| 85027 | <1% | 2,674 | $13K | |
| 82607 | <1% | 1,214 | $12K | |
| 81003 | <1% | 5,141 | $12K | |
| 87077 | <1% | 1,261 | $12K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,887 | $11K |
| 73030 | <1% | 565 | $9K | |
| 80081 | <1% | 95 | $9K | |
| 83605 | <1% | 1,135 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 248 | $9K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 713 | $8K |
| 83735 | <1% | 1,953 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,005 | $8K |
| 83690 | <1% | 1,381 | $8K | |
| 87040 | <1% | 952 | $7K | |
| 73630 | <1% | 310 | $7K | |
| 80076 | <1% | 582 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 151 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,114 | $6K |
| 73610 | <1% | 348 | $6K | |
| 82150 | <1% | 1,023 | $5K | |
| 84702 | <1% | 618 | $5K | |
| 80306 | <1% | 262 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $5K |
| 99283 | Emergency room visit (moderate) | <1% | 787 | $4K |
| 86901 | <1% | 487 | $4K | |
| 82962 | <1% | 868 | $4K | |
| 87807 | <1% | 392 | $4K | |
| 73130 | <1% | 165 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 871 | $4K |
| 85610 | <1% | 1,654 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,258 | $3K |
| 71020 | <1% | 270 | $3K | |
| 74019 | <1% | 141 | $3K | |
| 86900 | <1% | 487 | $3K | |
| 87186 | <1% | 566 | $3K | |
| 84153 | <1% | 356 | $3K | |
| 86803 | <1% | 195 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,008 | $3K |
| 82728 | <1% | 199 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,285 | $2K |
| 85379 | <1% | 275 | $2K | |
| 84439 | <1% | 311 | $2K | |
| 73110 | <1% | 115 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $2K |
| 86592 | <1% | 798 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,641 | $2K |
| 83540 | <1% | 336 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 15 | $2K |
| 93975 | <1% | 32 | $2K | |
| 83550 | <1% | 188 | $2K | |
| 86780 | <1% | 96 | $2K | |
| 82947 | <1% | 221 | $2K | |
| 85007 | <1% | 731 | $1K | |
| 82077 | <1% | 86 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 174 | $1K |
| 71010 | <1% | 211 | $1K | |
| 74022 | <1% | 53 | $1K | |
| 99284 | Emergency room visit (serious) | <1% | 896 | $1K |
| 74000 | <1% | 68 | $864.52 | |
| 80320 | <1% | 47 | $813.22 | |
| 84550 | <1% | 239 | $774.44 | |
| 80074 | <1% | 13 | $750.62 | |
| 87400 | <1% | 73 | $634.64 | |
| 73502 | <1% | 37 | $631.90 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 29 | $560.43 |
| 97001 | <1% | 20 | $540.15 | |
| 82677 | <1% | 18 | $483.56 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 26 | $464.22 |
| 87081 | <1% | 55 | $458.49 | |
| 85730 | <1% | 131 | $449.26 | |
| 82803 | <1% | 25 | $429.37 | |
| 86850 | <1% | 415 | $411.89 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17 | $355.48 |
| 82105 | <1% | 18 | $335.30 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 33 | $324.00 |
| 72040 | <1% | 20 | $308.14 | |
| 87340 | <1% | 183 | $306.94 | |
| 86336 | <1% | 18 | $304.78 | |
| 82570 | <1% | 47 | $301.27 | |
| 82565 | <1% | 33 | $290.87 | |
| 85018 | <1% | 118 | $289.51 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 665 | $285.99 |
| 0353U | <1% | 173 | $283.52 | |
| 82397 | <1% | 18 | $282.52 | |
| 83655 | <1% | 15 | $259.20 | |
| 90715 | <1% | 12 | $259.20 | |
| 86762 | <1% | 139 | $257.70 | |
| 97032 | <1% | 139 | $243.01 | |
| 87808 | <1% | 17 | $229.67 | |
| 82043 | <1% | 26 | $166.24 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $122.41 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 57 | $104.87 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 134 | $99.79 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24 | $91.98 |
| 82044 | <1% | 61 | $65.78 | |
| 81002 | <1% | 31 | $62.22 | |
| 87210 | <1% | 13 | $62.22 | |
| 85652 | <1% | 28 | $46.42 | |
| 81015 | <1% | 49 | $46.31 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 228 | $42.58 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 187 | $36.51 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 198 | $30.42 |
| 85014 | <1% | 14 | $20.28 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 205 | $16.10 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 220 | $8.95 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,036 | $7.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,948 | $6.83 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,843 | $5.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 305 | $1.11 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 14 | $0.65 |
| 36600 | 0% | 25 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 41 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,175 | $0.00 |
| 90686 | 0% | 16 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 16 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, TROY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Baptist Health Regional Hospitals | Fort Smith, AR | $17.49M |
| Baptist Health | Little Rock, AR | $16.48M |
| Baptist Health | North Little Rock, AR | $14.02M |
| Baptist Health | Arkadelphia, AR | $4.82M |
| Conway Community Services | Conway, AR | $4.12M |
| Baptist Health | Heber Springs, AR | $3.69M |
| Baptist Health | Little Rock, AR | $2.93M |
| Baptist Health | Malvern, AR | $2.68M |
| Baptist Health Regional Hospitals | Van Buren, AR | $2.46M |
| Baptist Health | Little Rock, AR | $1.83M |
| Baptist Health | Arkadelphia, AR | $1.51M |
| Baptist Health Hospitals | Stuttgart, AR | $901K |
| Baptist Health | Little Rock, AR | $780K |
| Baptist Health | North Little Rock, AR | $411K |
| Baptist Health | Monticello, AR | $367K |
| Baptist Health | Conway, AR | $142K |
| Baptist Health | Little Rock, AR | $88K |
| Baptist Health | Prescott, AR | $33K |
| Baptist Health | Malvern, AR | $31K |
| Baptist Health | Heber Springs, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.